The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the novel drug candidate FL118 for the treatment of patients with pancreatic cancer.
The U.S. Food and Drug Administration (FDA) approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma.
The FDA has approved Vyloy, a monoclonal antibody, for the treatment of gastric cancer in combination with chemotherapy, marking a significant step in targeted therapy for this disease.